Measured Wealth Private Client Group LLC Has $881,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Measured Wealth Private Client Group LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,512 shares of the company’s stock after selling 60 shares during the period. Measured Wealth Private Client Group LLC’s holdings in Eli Lilly and Company were worth $881,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Legacy Financial Group LLC acquired a new stake in Eli Lilly and Company during the third quarter worth about $35,000. Baker Ellis Asset Management LLC acquired a new position in shares of Eli Lilly and Company in the third quarter valued at $215,000. Mn Services Vermogensbeheer B.V. lifted its position in Eli Lilly and Company by 1.4% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 353,388 shares of the company’s stock worth $189,815,000 after purchasing an additional 5,000 shares during the period. Guyasuta Investment Advisors Inc. boosted its stake in Eli Lilly and Company by 0.8% during the third quarter. Guyasuta Investment Advisors Inc. now owns 3,047 shares of the company’s stock worth $1,637,000 after buying an additional 23 shares in the last quarter. Finally, Segment Wealth Management LLC increased its holdings in Eli Lilly and Company by 5.4% in the 3rd quarter. Segment Wealth Management LLC now owns 1,278 shares of the company’s stock valued at $686,000 after buying an additional 65 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on LLY. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 target price (up previously from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Morgan Stanley upped their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Truist Financial boosted their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Citigroup upped their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Trading Down 2.8 %

NYSE:LLY traded down $20.94 on Friday, hitting $734.97. 4,595,138 shares of the stock were exchanged, compared to its average volume of 2,629,045. The stock has a market capitalization of $698.52 billion, a price-to-earnings ratio of 108.24, a P/E/G ratio of 1.50 and a beta of 0.37. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78. The company has a debt-to-equity ratio of 1.90, a quick ratio of 0.73 and a current ratio of 1.35. The company’s 50-day moving average price is $761.06 and its 200 day moving average price is $671.38.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The company’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.62 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 13.83 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.